Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLA2G2A | P14555 | 10/20 | 0.43 |
| ▸ | PLA2G10 | O15496 | 4/20 | 0.43 |
| ▸ | PLA2G1B | P04054 | 3/20 | 0.42 |
| ▸ | PLA2G5 | P39877 | 3/20 | 0.42 |
| ▸ | TLR2 | O60603 | 8/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25967589 | 0.93 | PLA2G2A (0.43) | PLA2G2APLA2G10PLA2G1BPLA2G5TLR2 | |
| SCHEMBL10043029 | 0.93 | PLA2G2A (0.43) | PLA2G2APLA2G10PLA2G1BPLA2G5TLR2 | |
| SCHEMBL24304694 | 0.87 | PLA2G2A (0.44) | PLA2G2APLA2G10PLA2G1BPLA2G5TLR2 | |
| SCHEMBL25971807 | 0.86 | TLR2 (0.44) | PLA2G2APLA2G10PLA2G1BPLA2G5TLR2 | |
| SCHEMBL24304580 | 0.84 | PLA2G2A (0.47) | PLA2G2APLA2G10PLA2G1BPLA2G5TLR2 | |
| SCHEMBL25971831 | 0.84 | TLR2 (0.46) | PLA2G2APLA2G10PLA2G1BPLA2G5TLR2 | |
| SCHEMBL24304595 | 0.82 | PLA2G2A (0.37) | PLA2G2APLA2G10PLA2G1BPLA2G5 | |
| SCHEMBL24304365 | 0.82 | PLA2G2A (0.37) | PLA2G2APLA2G10PLA2G1BPLA2G5TLR2 | |
| SCHEMBL24304381 | 0.80 | TLR2 (0.48) | PLA2G2APLA2G10PLA2G1BPLA2G5TLR2 | |
| SCHEMBL29413318 | 0.80 | PLA2G2A (0.36) | PLA2G2APLA2G10PLA2G1BPLA2G5TLR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12473314-B2 | Phospholipid compounds and uses thereof | GILEAD SCIENCES, INC. (US) | 2025-11-18 | — | — | US | disclosed |
| EP-4537828-A2 | PHOSPHOLIPID COMPOUNDS AND USES THEREOF | Gilead Sciences, Inc. (US) | 2025-04-16 | — | — | EP | disclosed |
| EP-4200301-B1 | PHOSPHOLIPID COMPOUNDS AND USES THEREOF | GILEAD SCIENCES INC (US) | 2025-02-26 | — | — | EP | disclosed |
| US-12030904-B2 | Phospholipid compounds and uses thereof | GILEAD SCIENCES, INC. (US) | 2024-07-09 | — | — | US | disclosed |
| US-12030904-B2 | Phospholipid compounds and uses thereof | GILEAD SCIENCES, INC. (US) | 2024-07-09 | — | — | US | disclosed |
| US-20240025932-A1 | PHOSPHOLIPID COMPOUNDS AND USES THEREOF | GILEAD SCIENCES, INC. | 2024-01-25 | — | — | US | disclosed |
| US-20240025932-A1 | PHOSPHOLIPID COMPOUNDS AND USES THEREOF | GILEAD SCIENCES, INC. | 2024-01-25 | — | — | US | disclosed |
| US-11773122-B2 | Phospholipid compounds and uses thereof | GILEAD SCIENCES. INC. (US) | 2023-10-03 | — | — | US | disclosed |
| US-11773122-B2 | Phospholipid compounds and uses thereof | GILEAD SCIENCES. INC. (US) | 2023-10-03 | — | — | US | disclosed |
| US-20230250117-A1 | PHOSPHOLIPID COMPOUNDS AND USES THEREOF | GILEAD SCIENCES, INC. | 2023-08-10 | — | — | US | disclosed |
| US-20230250117-A1 | PHOSPHOLIPID COMPOUNDS AND USES THEREOF | GILEAD SCIENCES, INC. | 2023-08-10 | — | — | US | disclosed |
| EP-4200301-A1 | PHOSPHOLIPID COMPOUNDS AND USES THEREOF | GILEAD SCIENCES, INC. (US) | 2023-06-28 | — | — | EP | disclosed |
| US-20220081455-A1 | PHOSPHOLIPID COMPOUNDS AND USES THEREOF | GILEAD SCIENCES, INC. | 2022-03-17 | — | — | US | disclosed |
| WO-2022046631-A1 | PHOSPHOLIPID COMPOUNDS AND USES THEREOF | GILEAD SCIENCES, INC. (US) | 2022-03-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12030904-B2 | Phospholipid compounds and uses thereof | PHOSPHO1, SGMS2, SGMS1 | PLA2G2A 29/4885PLA2G10 31/4885PLA2G1B 22/4885 |
| US-20230250117-A1 | PHOSPHOLIPID COMPOUNDS AND USES THEREOF | PHOSPHO1, SGMS2, SGMS1 | PLA2G2A 29/4885PLA2G10 31/4885PLA2G1B 22/4885 |
| US-20220081455-A1 | PHOSPHOLIPID COMPOUNDS AND USES THEREOF | PHOSPHO1, SGMS2, SGMS1 | PLA2G2A 29/4885PLA2G10 31/4885PLA2G1B 22/4885 |
| US-20240025932-A1 | PHOSPHOLIPID COMPOUNDS AND USES THEREOF | PHOSPHO1, SGMS2, SGMS1 | PLA2G2A 29/4885PLA2G10 31/4885PLA2G1B 22/4885 |
| US-11773122-B2 | Phospholipid compounds and uses thereof | PHOSPHO1, SGMS2, SGMS1 | PLA2G2A 29/4885PLA2G10 31/4885PLA2G1B 22/4885 |
| US-12473314-B2 | Phospholipid compounds and uses thereof | PHOSPHO1, SGMS2, SGMS1 | PLA2G2A 29/4885PLA2G10 31/4885PLA2G1B 22/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.